Notably, the upregulation of PD‐L1, IDO, and regulatory Tregs is driven by CD8+ T cells [106], suggesting that combination therapies targeting these markers may yield synergistic antitumor effects, particularly in tumor microenvironments with pre‐existing T‐cell inflammation. Here, IDO1 is linked to neoplasm.